Osimertinib, a first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC), induces severe lymphocytopenia (Grade ≥3: 6.1%) (1, 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.